Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
yHJmJ7MyUxBAg5sv
Listen
